Cellectar Biosciences, Inc. (CLRB) — SEC Filings
Cellectar Biosciences, Inc. (CLRB) — 50 SEC filings. Latest: 8-K (May 8, 2026). Includes 29 8-K, 6 SC 13G/A, 5 10-Q.
View Cellectar Biosciences, Inc. on SEC EDGAR
Overview
Cellectar Biosciences, Inc. (CLRB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Cellectar Biosciences, Inc. (CLRB) reported a significant decrease in net loss for the nine months ended September 30, 2025, narrowing to $16,495,816 from $42,226,073 in the prior year, a 60.9% improvement. This was primarily driven by a substantial reduction in operating expenses, with research and
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Cellectar Biosciences, Inc. is neutral.
Filing Type Overview
Cellectar Biosciences, Inc. (CLRB) has filed 29 8-K, 5 10-Q, 2 S-1, 1 S-1/A, 1 DEFA14A, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 10-K/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CLRB's 40 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 17 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$16,495,816 |
| EPS | -$7.82 |
| Cash Position | $12,554,289 |
| Total Assets | $14,627,590 |
| Total Debt | $5,248,261 |
Key Executives
- James V. Caruso
Industry Context
Cellectar Biosciences operates in the highly competitive biotechnology sector, focusing on developing targeted therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Cellectar often rely on substantial external funding to advance their pipelines through clinical trials.
Top Tags
financials (9) · disclosure (5) · Biotechnology (4) · SEC Filing (4) · 8-K (4) · corporate-governance (4) · financial-reporting (4) · financial-condition (3) · equity-sale (3) · operations (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $16,495,816 | for the nine months ended September 30, 2025, a 60.9% decrease from $42,226,073 in 2024 |
| Research and Development Expenses | $8,340,200 | for the nine months ended September 30, 2025, a 58.1% decrease from $19,927,019 in 2024 |
| General and Administrative Expenses | $8,949,015 | for the nine months ended September 30, 2025, a 53.1% decrease from $19,105,853 in 2024 |
| Cash and Cash Equivalents | $12,554,289 | as of September 30, 2025, down from $23,288,607 at December 31, 2024 |
| Available Liquidity | $15.6 million | to fund operations over the next twelve months beyond the issuance date |
| Accumulated Deficit | $263,838,000 | as of September 30, 2025 |
| Shares of Common Stock Outstanding | 4,240,134 | as of November 10, 2025 |
| Cash Provided by Financing Activities | $8,039,763 | for the nine months ended September 30, 2025 |
| Shares offered by selling stockholders | 2,096,188 Shares | Represents potential dilution from warrant exercises and resales |
| Gross proceeds from October 2025 warrant inducement | $5.8 million | Cash infusion for the company from warrant exercises |
| Exercise price of Existing Warrants | $5.25 | Price at which 1,048,094 Existing Warrants were exercised |
| Exercise price of Inducement Warrants | $6.00 | Price for Series I and Series II Inducement Warrants |
| Shares from exercised Existing Warrants | 1,048,094 shares | Number of shares underlying the Existing Warrants exercised in October 2025 |
| Shares underlying Series I Inducement Warrants | 1,048,094 shares | Potential future dilution from Series I Inducement Warrants |
| Shares underlying Series II Inducement Warrants | 1,048,094 shares | Potential future dilution from Series II Inducement Warrants |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cellectar Biosciences, Inc. (CLRB)?
Cellectar Biosciences, Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 29 8-K, 6 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CLRB filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cellectar Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cellectar Biosciences, Inc. (CLRB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cellectar Biosciences, Inc.?
Key financial highlights from Cellectar Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CLRB?
The investment thesis for CLRB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cellectar Biosciences, Inc.?
Key executives identified across Cellectar Biosciences, Inc.'s filings include James V. Caruso.
What are the main risk factors for Cellectar Biosciences, Inc. stock?
Of CLRB's 40 assessed filings, 5 were flagged high-risk, 18 medium-risk, and 17 low-risk.
What are recent predictions and forward guidance from Cellectar Biosciences, Inc.?
Forward guidance and predictions for Cellectar Biosciences, Inc. are extracted from SEC filings as they are enriched.